Form D · Pharmaceuticals
Telemachus Therapeutics, Inc.
Pittsburgh, PA · CIK 0002152986
Offering snapshot reported Sep 2, 2026 · SEC filing
- Reported sold
- $125K Offering amount: $1.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Aug 20, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 2, 2026 | Initial | $125,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-596219
Simple Agreement for Future Equity (SAFE)
Source: Form D, filed Sep 2, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Bozik | Director, Executive, Promoter |
| Gregory Hebrank | Director, Executive, Promoter |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
401 Woodhaven Drive
Pittsburgh, PA, 15090
Phone: 412-527-6630
Pittsburgh, PA, 15090
Phone: 412-527-6630